Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.
Ontology highlight
ABSTRACT: Conventional treatments for pancreatic cancer are largely ineffective, and the prognosis for the vast majority of patients is poor. Clearly, new treatment options are desperately needed. Immunotherapy offers hope for the development of treatments for pancreatic cancer. A central requirement for the efficacy of this approach is the existence of cancer antigen-specific T cells, but these are often not present or difficult to isolate for most pancreatic tumors. Nevertheless, specific T cells can be generated using genetic modification to express chimeric antigen receptors (CAR), which can enable T cell responses against pancreatic tumor cells. CAR T cells can be produced ex vivo and expanded in vitro for infusion into patients. Remarkable responses have been documented using CAR
SUBMITTER: Ali AI
PROVIDER: S-EPMC6379296 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA